The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1246-1254

  Wei, Jinhuan ^a   Cheang, Tuckyun ^a   Tang, Bing ^a   Xia, Haoming ^a   Xing, Zhouhao ^b   Chen, Zhenhua ^a   Fang, Yong ^a   Chen, Wei ^a   Xu, Anwu ^b   Wang, Shenming ^a   Luo, Junhang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

AIB1; Bladder cancer; Calcium carbonate; Gene therapy; Nanocomposite; SiRNA delivery

Indexed keywords

AIB1; AMORPHOUS CALCIUM CARBONATE; APOPTOSIS INDUCTION; BLADDER CANCERS; BREAST CANCER; CANCER GENE THERAPY; CELL-CYCLE ARREST; DOWN-REGULATION; FUNCTIONALIZED; GENE CARRIER; GENE VECTORS; HUMAN BLADDER CANCER; IN-VITRO; IN-VIVO; INTRATUMORAL INJECTION; NANO-COMPOSITE PARTICLE; NONVIRAL; PROLIFERATION INHIBITION; SIGNALING PATHWAYS; SIRNA DELIVERY; SMALL INTERFERING RNA (SIRNA); TRANSFECTION EFFICIENCY; TUMOR GROWTH;

CALCIUM CARBONATE; CELL DEATH; DISEASES; GENE THERAPY; NANOCOMPOSITES; NANOPARTICLES; RNA; TISSUE;

MOLECULAR BIOLOGY;

CALCIUM CARBONATE; NANOCOMPOSITE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CALCIUM CARBONATE; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; NANOCAPSULES; RNA, SMALL INTERFERING; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84870308901     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.068     Document Type: Article

References (48)

1. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
2. Sokolova V., Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl 2008, 47:1382-1395.
3. Sun T.M., Du J.Z., Yao Y.D., Mao C.Q., Dou S., Huang S.Y., et al. Simultaneous delivery of siRNA and paclitaxel via a " two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
4. Ji A.M., Su D., Che O., Li W.S., Sun L., Zhang Z.Y., et al. Functional gene silencing mediated by chitosan/siRNA nanocomplexes. Nanotechnology 2009, 20:405103.
5. Beloor J., Choi C.S., Nam H.Y., Park M., Kim S.H., Jackson A., et al. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials 2012, 33:1640-1650.
6. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
7. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581-593.
8. Anderson W.F. Human gene therapy. Nature 1998, 392:25-30.
9. Li W., Szoka F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007, 24:438-449.
10. Li S.D., Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007, 123:181-183.
11. Tseng W.C., Haselton F.R., Giorgio T.D. Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression. J Biol Chem 1997, 272:25641-25647.
12. Varga C.M., Hong K., Lauffenburger D.A. Quantitative analysis of synthetic gene delivery vector design properties. Mol Ther 2001, 4:438-446.
13. Jere D., Yoo M.K., Arote R., Kim T.H., Cho M.H., Nah J.W., et al. Poly (amino ester) composed of poly (ethylene glycol) and aminosilane prepared by combinatorial chemistry as a gene carrier. Pharm Res 2008, 25:875-885.
14. Akinc A., Lynn D.M., Anderson D.G., Langer R. Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery. J Am Chem Soc 2003, 125:5316-5323.
15. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J.R. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A 1996, 93:4897-4902.
16. Gan Q., Wang T., Cochrane C., McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 2005, 44:65-73.
17. Kang J.H., Asai D., Kim J.H., Mori T., Toita R., Tomiyama T., et al. Design of polymeric carriers for cancer-specific gene targeting: utilization of abnormal protein kinase Calpha activation in cancer cells. J Am Chem Soc 2008, 130:14906-14907.
18. Torchilin V.P. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006, 58:1532-1555.
19. del Pozo-Rodriguez A., Pujals S., Delgado D., Solinis M.A., Gascon A.R., Giralt E., et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J Control Release 2009, 133:52-59.
20. Roy I., Ohulchanskyy T.Y., Bharali D.J., Pudavar H.E., Mistretta R.A., Kaur N., et al. Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. Proc Natl Acad Sci U S A 2005, 102:279-284.
21. Rosi N.L., Giljohann D.A., Thaxton C.S., Lytton-Jean A.K., Han M.S., Mirkin C.A. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006, 312:1027-1030.
22. Kam N.W., Liu Z., Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005, 127:12492-12493.
23. Xu A.W., Yu Q., Dong W.F., Antonietti M., Cölfen H. Stable amorphous CaCO3 microparticles with hollow spherical superstructures stabilized by phytic acid. Adv Mater 2005, 17:2217-2221.
24. He X.W., Liu T., Chen Y.X., Cheng D.J., Li X.R., Xiao Y., et al. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther 2008, 15:193-202.
25. Cheang T.Y., Wang S.M., Hu Z.J., Xing Z.H., Chang G.Q., Yao C., et al. Calcium carbonate/CaIP6 nanocomposite particles as gene delivery vehicles for human vascular smooth muscle cells. J Mater Chem 2010, 20:8050-8055.
26. Wang Y., Wu M.C., Sham J.S., Zhang W., Wu W.Q., Guan X.Y. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002, 95:2346-2352.
27. Xie D., Sham J.S., Zeng W.F., Lin H.L., Bi J., Che L.H., et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol 2005, 36:777-783.
28. Henke R.T., Haddad B.R., Kim S.E., Rone J.D., Mani A., Jessup J.M., et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 2004, 10:6134-6142.
29. Liu M.Z., Xie D., Mai S.J., Tong Z.T., Shao J.Y., Fu Y.S., et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol 2008, 129:728-734.
30. He L.R., Liu M.Z., Li B.K., Rao H.L., Deng H.X., Guan X.Y., et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci 2009, 100:1591-1596.
31. He L.R., Zhao H.Y., Li B.K., Zhang L.J., Liu M.Z., Kung H.F., et al. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol 2010, 21:1675-1681.
32. Kefalopoulou Z., Tzelepi V., Zolota V., Grivas P.D., Christopoulos C., Kalofonos H., et al. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. J Neurooncol 2012, 106:23-31.
33. Luo J.H., Xie D., Liu M.Z., Chen W., Liu Y.D., Wu G.Q., et al. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer 2008, 122:2554-2561.
34. Chung A.C., Zhou S., Liao L., Tien J.C., Greenberg N.M., Xu J. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 2007, 67:5965-5975.
35. Zhou H.J., Yan J., Luo W., Ayala G., Lin S.H., Erdem H., et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005, 65:7976-7983.
36. Qin L., Liao L., Redmond A., Young L., Yuan Y., Chen H., et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 2008, 28:5937-5950.
37. Tikkanen M.K., Carter D.J., Harris A.M., Le H.M., Azorsa D.O., Meltzer P.S., et al. Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells. Proc Natl Acad Sci U S A 2000, 97:12536-12540.
38. Kuang S.Q., Liao L., Zhang H., Lee A.V., O'Malley B.W., Xu J. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 2004, 64:1875-1885.
39. Xu J.M., Liao L., Ning C., Yoshida-Komiya H., Deng C.X., O'Malley B.W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. P Natl Acad Sci U S A 2000, 97:6379-6384.
40. Colo G.P., Rosato R.R., Grant S., Costas M.A. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett 2007, 581:5075-5081.
41. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
42. Ma G., Ren Y., Wang K., He J.J. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci 2011, 7:664-672.
43. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Hobel S., et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006, 17:751-766.
44. Niu X.Y., Peng Z.L., Duan W.Q., Wang H., Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006, 16:743-751.
45. Zhou G., Hashimoto Y., Kwak I., Tsai S.Y., Tsai M.J. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 2003, 23:7742-7755.
46. Torres-Arzayus M.I., Font de Mora J., Yuan J., Vazquez F., Bronson R., Rue M., et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004, 6:263-274.
47. Chen Q., Li W., Wan Y., Xia X., Wu Q., Chen Y., et al. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 2012, 55:1820-1829.
48. Oh A., List H.J., Reiter R., Mani A., Zhang Y., Gehan E., et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 2004, 64:8299-8308.